ripertamab
Phase 3Monoclonal antibody
ripertamab is one of 49 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.
4
Indications
4
Total Trials
4
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Nephrotic Syndrome
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Cellcept
RocheApproved
Farxiga
AstraZenecaApproved
Neoral
NovartisApproved
Lovenox
SanofiApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Thalitone
Jazz PharmaceuticalsApproved
Rayos
RRoxane Laboratories
Approved
Aldactone
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nephrotic Syndrome1 trial
Chronic Inflammatory Demyelinating Polyneuropathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ripertamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZhongming Qiu